Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database
To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT). The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patien...
Gespeichert in:
| Veröffentlicht in: | Saudi medical journal 2024-09, Vol.45 (9), p.900-910 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 910 |
|---|---|
| container_issue | 9 |
| container_start_page | 900 |
| container_title | Saudi medical journal |
| container_volume | 45 |
| creator | An, Qiuying Su, Yuhao Wang, Yajing Zhen, Chanjun Bai, Wenwen Fu, Liyuan Liu, Yibing Zhang, Ping Zhou, Zhiguo |
| description | To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT).
The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patients were split into the adjuvant radiotherapy with or without chemotherapy (RT±CT) and the adjuvant chemotherapy (CT) groups. The process of propensity score matching (PSM) was employed.
Following PSM, 157 patients in total were recruited in each treatment group. There were no significant variations in either overall survival (OS) or cancer-specific survival (CSS) between the RT±CT and CT groups (median OS: 28 months versus. 51 months,
=0.063; median CSS: 31 months versus. 52 months,
=0.16). Within the CT group, patients with ypI/II or cI/II tumor stage, positive lymph node ratio (LNR) ≤0.1, and tumor size ≥50 mm ( |
| doi_str_mv | 10.15537/smj.2024.45.9.20240045 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11376696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A808340177</galeid><sourcerecordid>A808340177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-d3ecbba9c4e46fc59746d554623853f549d94d297bff1143e15f3e6f77ceb0ad3</originalsourceid><addsrcrecordid>eNptUttq3DAUFKWl2ab9hVbQZ7uSdbOfwhK2bSBQ6OVZyNLRWstaMpazZf-mn1ol2ywJFIEk5swMGjQIfaCkpkIw9SmPu7ohDa-5qLuHGyFcvEArKkVbMarES7QiTHWVaFp-gd7kvCOESUnka3TBuoa2XKgV-nOT8ZTykiaYzRIOgI3b3R1MXPBsXEjLUPDpiCNYyNnMR-zTjKdChbhk_DssA4acpsFsweyxNdHCjI1fyh4hnc3sAGN66niF1xGbaPbHHDLuTQaHU8Rlin9sNt-xM4u5R9-iV97sM7z7d16iX583P6-_Vrffvtxcr28ry2izVI6B7XvTWQ5ceis6xaUTgsuGtYJ5wTvXcdd0qveeUs6ACs9AeqUs9MQ4domuTr7TXT-CsyXebPZ6msNYUutkgn4-iWHQ23TQlDIlZSeLw8eTw9bsQYfoU-HZMWSr1y1pGSdUqcKq_8Mqy8EYbIrgQ8GfCdRJYOeU8wz-_CZK9EMZdCmDvq-A5kJ3-rEMRfn-aaSz7vH32V-lC7YO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>An, Qiuying ; Su, Yuhao ; Wang, Yajing ; Zhen, Chanjun ; Bai, Wenwen ; Fu, Liyuan ; Liu, Yibing ; Zhang, Ping ; Zhou, Zhiguo</creator><creatorcontrib>An, Qiuying ; Su, Yuhao ; Wang, Yajing ; Zhen, Chanjun ; Bai, Wenwen ; Fu, Liyuan ; Liu, Yibing ; Zhang, Ping ; Zhou, Zhiguo</creatorcontrib><description>To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT).
The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patients were split into the adjuvant radiotherapy with or without chemotherapy (RT±CT) and the adjuvant chemotherapy (CT) groups. The process of propensity score matching (PSM) was employed.
Following PSM, 157 patients in total were recruited in each treatment group. There were no significant variations in either overall survival (OS) or cancer-specific survival (CSS) between the RT±CT and CT groups (median OS: 28 months versus. 51 months,
=0.063; median CSS: 31 months versus. 52 months,
=0.16). Within the CT group, patients with ypI/II or cI/II tumor stage, positive lymph node ratio (LNR) ≤0.1, and tumor size ≥50 mm (
<0.05) had higher OS compared to the RT±CT groups. Among patients with cT3-4 tumors in N-stage downstaging group, the OS and CSS were significantly greater for those underwent RT±CT as opposed to the CT group (5-year OS:56.6% versus 19.4%,
=0.042; 5-year CSS:67.9% versus. 19.4%,
=0.023). Multivariate Cox regression analysis identified the tumor histology grade as an independent prognostic factor of OS and CSS.
Radiotherapy-based adjuvant therapy does not significantly improve the prognosis of EC patients after NCRT, although it may provide a survival benefit for patients with cT3-4 tumors in N-stage downstaging.</description><identifier>ISSN: 0379-5284</identifier><identifier>EISSN: 1658-3175</identifier><identifier>DOI: 10.15537/smj.2024.45.9.20240045</identifier><identifier>PMID: 39218457</identifier><language>eng</language><publisher>Saudi Arabia: Saudi Medical Journal</publisher><subject>Adjuvant treatment ; Aged ; Cancer ; Care and treatment ; Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Development and progression ; Esophageal cancer ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Esophagectomy ; Female ; Humans ; Male ; Methods ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Observations ; Original ; Patient outcomes ; Postoperative period ; Propensity Score ; Radiotherapy ; Radiotherapy, Adjuvant ; SEER Program ; Survival Rate</subject><ispartof>Saudi medical journal, 2024-09, Vol.45 (9), p.900-910</ispartof><rights>Copyright: © Saudi Medical Journal.</rights><rights>COPYRIGHT 2024 Saudi Medical Journal</rights><rights>Copyright: © Saudi Medical Journal 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-5373-8098</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376696/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376696/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39218457$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>An, Qiuying</creatorcontrib><creatorcontrib>Su, Yuhao</creatorcontrib><creatorcontrib>Wang, Yajing</creatorcontrib><creatorcontrib>Zhen, Chanjun</creatorcontrib><creatorcontrib>Bai, Wenwen</creatorcontrib><creatorcontrib>Fu, Liyuan</creatorcontrib><creatorcontrib>Liu, Yibing</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><creatorcontrib>Zhou, Zhiguo</creatorcontrib><title>Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database</title><title>Saudi medical journal</title><addtitle>Saudi Med J</addtitle><description>To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT).
The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patients were split into the adjuvant radiotherapy with or without chemotherapy (RT±CT) and the adjuvant chemotherapy (CT) groups. The process of propensity score matching (PSM) was employed.
Following PSM, 157 patients in total were recruited in each treatment group. There were no significant variations in either overall survival (OS) or cancer-specific survival (CSS) between the RT±CT and CT groups (median OS: 28 months versus. 51 months,
=0.063; median CSS: 31 months versus. 52 months,
=0.16). Within the CT group, patients with ypI/II or cI/II tumor stage, positive lymph node ratio (LNR) ≤0.1, and tumor size ≥50 mm (
<0.05) had higher OS compared to the RT±CT groups. Among patients with cT3-4 tumors in N-stage downstaging group, the OS and CSS were significantly greater for those underwent RT±CT as opposed to the CT group (5-year OS:56.6% versus 19.4%,
=0.042; 5-year CSS:67.9% versus. 19.4%,
=0.023). Multivariate Cox regression analysis identified the tumor histology grade as an independent prognostic factor of OS and CSS.
Radiotherapy-based adjuvant therapy does not significantly improve the prognosis of EC patients after NCRT, although it may provide a survival benefit for patients with cT3-4 tumors in N-stage downstaging.</description><subject>Adjuvant treatment</subject><subject>Aged</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemoradiotherapy, Adjuvant</subject><subject>Chemotherapy, Adjuvant</subject><subject>Development and progression</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagectomy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Observations</subject><subject>Original</subject><subject>Patient outcomes</subject><subject>Postoperative period</subject><subject>Propensity Score</subject><subject>Radiotherapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>SEER Program</subject><subject>Survival Rate</subject><issn>0379-5284</issn><issn>1658-3175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUttq3DAUFKWl2ab9hVbQZ7uSdbOfwhK2bSBQ6OVZyNLRWstaMpazZf-mn1ol2ywJFIEk5swMGjQIfaCkpkIw9SmPu7ohDa-5qLuHGyFcvEArKkVbMarES7QiTHWVaFp-gd7kvCOESUnka3TBuoa2XKgV-nOT8ZTykiaYzRIOgI3b3R1MXPBsXEjLUPDpiCNYyNnMR-zTjKdChbhk_DssA4acpsFsweyxNdHCjI1fyh4hnc3sAGN66niF1xGbaPbHHDLuTQaHU8Rlin9sNt-xM4u5R9-iV97sM7z7d16iX583P6-_Vrffvtxcr28ry2izVI6B7XvTWQ5ceis6xaUTgsuGtYJ5wTvXcdd0qveeUs6ACs9AeqUs9MQ4domuTr7TXT-CsyXebPZ6msNYUutkgn4-iWHQ23TQlDIlZSeLw8eTw9bsQYfoU-HZMWSr1y1pGSdUqcKq_8Mqy8EYbIrgQ8GfCdRJYOeU8wz-_CZK9EMZdCmDvq-A5kJ3-rEMRfn-aaSz7vH32V-lC7YO</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>An, Qiuying</creator><creator>Su, Yuhao</creator><creator>Wang, Yajing</creator><creator>Zhen, Chanjun</creator><creator>Bai, Wenwen</creator><creator>Fu, Liyuan</creator><creator>Liu, Yibing</creator><creator>Zhang, Ping</creator><creator>Zhou, Zhiguo</creator><general>Saudi Medical Journal</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5373-8098</orcidid></search><sort><creationdate>20240901</creationdate><title>Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database</title><author>An, Qiuying ; Su, Yuhao ; Wang, Yajing ; Zhen, Chanjun ; Bai, Wenwen ; Fu, Liyuan ; Liu, Yibing ; Zhang, Ping ; Zhou, Zhiguo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-d3ecbba9c4e46fc59746d554623853f549d94d297bff1143e15f3e6f77ceb0ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adjuvant treatment</topic><topic>Aged</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemoradiotherapy, Adjuvant</topic><topic>Chemotherapy, Adjuvant</topic><topic>Development and progression</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagectomy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Observations</topic><topic>Original</topic><topic>Patient outcomes</topic><topic>Postoperative period</topic><topic>Propensity Score</topic><topic>Radiotherapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>SEER Program</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>An, Qiuying</creatorcontrib><creatorcontrib>Su, Yuhao</creatorcontrib><creatorcontrib>Wang, Yajing</creatorcontrib><creatorcontrib>Zhen, Chanjun</creatorcontrib><creatorcontrib>Bai, Wenwen</creatorcontrib><creatorcontrib>Fu, Liyuan</creatorcontrib><creatorcontrib>Liu, Yibing</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><creatorcontrib>Zhou, Zhiguo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Saudi medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>An, Qiuying</au><au>Su, Yuhao</au><au>Wang, Yajing</au><au>Zhen, Chanjun</au><au>Bai, Wenwen</au><au>Fu, Liyuan</au><au>Liu, Yibing</au><au>Zhang, Ping</au><au>Zhou, Zhiguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database</atitle><jtitle>Saudi medical journal</jtitle><addtitle>Saudi Med J</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>45</volume><issue>9</issue><spage>900</spage><epage>910</epage><pages>900-910</pages><issn>0379-5284</issn><eissn>1658-3175</eissn><abstract>To evaluate the outcomes of adjuvant radiotherapy in patients with esophageal cancer (EC) who underwent esophagectomy following neoadjuvant chemoradiotherapy (NCRT).
The data of EC patients who received adjuvant therapy after NCRT between 2004 to 2019 was retrieved from the SEER database. The patients were split into the adjuvant radiotherapy with or without chemotherapy (RT±CT) and the adjuvant chemotherapy (CT) groups. The process of propensity score matching (PSM) was employed.
Following PSM, 157 patients in total were recruited in each treatment group. There were no significant variations in either overall survival (OS) or cancer-specific survival (CSS) between the RT±CT and CT groups (median OS: 28 months versus. 51 months,
=0.063; median CSS: 31 months versus. 52 months,
=0.16). Within the CT group, patients with ypI/II or cI/II tumor stage, positive lymph node ratio (LNR) ≤0.1, and tumor size ≥50 mm (
<0.05) had higher OS compared to the RT±CT groups. Among patients with cT3-4 tumors in N-stage downstaging group, the OS and CSS were significantly greater for those underwent RT±CT as opposed to the CT group (5-year OS:56.6% versus 19.4%,
=0.042; 5-year CSS:67.9% versus. 19.4%,
=0.023). Multivariate Cox regression analysis identified the tumor histology grade as an independent prognostic factor of OS and CSS.
Radiotherapy-based adjuvant therapy does not significantly improve the prognosis of EC patients after NCRT, although it may provide a survival benefit for patients with cT3-4 tumors in N-stage downstaging.</abstract><cop>Saudi Arabia</cop><pub>Saudi Medical Journal</pub><pmid>39218457</pmid><doi>10.15537/smj.2024.45.9.20240045</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5373-8098</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0379-5284 |
| ispartof | Saudi medical journal, 2024-09, Vol.45 (9), p.900-910 |
| issn | 0379-5284 1658-3175 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11376696 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adjuvant treatment Aged Cancer Care and treatment Chemoradiotherapy, Adjuvant Chemotherapy, Adjuvant Development and progression Esophageal cancer Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Esophagectomy Female Humans Male Methods Middle Aged Neoadjuvant Therapy Neoplasm Staging Observations Original Patient outcomes Postoperative period Propensity Score Radiotherapy Radiotherapy, Adjuvant SEER Program Survival Rate |
| title | Is postoperative adjuvant radiotherapy necessary for patients with esophageal cancer after neoadjuvant chemoradiotherapy? An analysis based on the SEER database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A25%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20postoperative%20adjuvant%20radiotherapy%20necessary%20for%20patients%20with%20esophageal%20cancer%20after%20neoadjuvant%20chemoradiotherapy?%20An%20analysis%20based%20on%20the%20SEER%20database&rft.jtitle=Saudi%20medical%20journal&rft.au=An,%20Qiuying&rft.date=2024-09-01&rft.volume=45&rft.issue=9&rft.spage=900&rft.epage=910&rft.pages=900-910&rft.issn=0379-5284&rft.eissn=1658-3175&rft_id=info:doi/10.15537/smj.2024.45.9.20240045&rft_dat=%3Cgale_pubme%3EA808340177%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/39218457&rft_galeid=A808340177&rfr_iscdi=true |